

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM490039

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
NeuMoDx, Molecular, Inc.		09/13/2018	Corporation:
RECEIVING PARTY DATA			
Name:	Venture Lending & Leasing IX, Inc.		
Street Address:	104 La Mesa Drive, Suite 102		
City:	Portola Valley		
State/Country:	CALIFORNIA		
Postal Code:	94028		
Entity Type:	Corporation: MARYLAND		
Name:	Venture Lending & Leasing VIII, Inc.		
Street Address:	104 La Mesa Drive, Suite 102		
City:	Portola Valley		
State/Country:	CALIFORNIA		
Postal Code:	94028		
Entity Type:	Corporation: MARYLAND		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	87175050	NEUMODX	
CORRESPONDENCE DATA			
Fax Number:	4157774961		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	415 981 1400		
Email:	nsust@greeneradovsky.com		
Correspondent Name:	JEFFREY T. KLUGMAN		
Address Line 1:	FOUR EMBARCADERO CENTER, SUITE 4000		
Address Line 4:	SAN FRANCISCO, CALIFORNIA 94111		
NAME OF SUBMITTER:	JEFFREY T. KLUGMAN		
SIGNATURE:	/JEFFREY T. KLUGMAN/		
DATE SIGNED:	09/14/2018		

OP \$40.00 87175050

Total Attachments: 13

source=NeuMoDx Molecular, Inc. 89-0427 IPSA#page1.tif
source=NeuMoDx Molecular, Inc. 89-0427 IPSA#page2.tif
source=NeuMoDx Molecular, Inc. 89-0427 IPSA#page3.tif
source=NeuMoDx Molecular, Inc. 89-0427 IPSA#page4.tif
source=NeuMoDx Molecular, Inc. 89-0427 IPSA#page5.tif
source=NeuMoDx Molecular, Inc. 89-0427 IPSA#page6.tif
source=NeuMoDx Molecular, Inc. 89-0427 IPSA#page7.tif
source=NeuMoDx Molecular, Inc. 89-0427 IPSA#page8.tif
source=NeuMoDx Molecular, Inc. 89-0427 IPSA#page9.tif
source=NeuMoDx Molecular, Inc. 89-0427 IPSA#page10.tif
source=NeuMoDx Molecular, Inc. 89-0427 IPSA#page11.tif
source=NeuMoDx Molecular, Inc. 89-0427 IPSA#page12.tif
source=NeuMoDx Molecular, Inc. 89-0427 IPSA#page13.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (this "Agreement") is made as of September 13, 2018, between NEUMODX MOLECULAR, INC., a Delaware corporation ("Grantor"), and VENTURE LENDING & LEASING VIII, INC. ("VLL8") and VENTURE LENDING & LEASING IX, INC. ("VLL9"), both Maryland corporations (sometimes referred to herein individually and together as "Secured Party").

RECITALS

A. Pursuant to that certain Loan and Security Agreement of even date herewith between Grantor, as borrower, and Secured Party, as lender (as amended, restated, supplemented or otherwise modified from time to time, the "Loan Agreement"), Secured Party has agreed to make certain advances of money and to extend certain financial accommodations to Grantor (the "Loans") in the amounts and manner set forth in the Loan Agreement. All capitalized terms used herein without definition shall have the meanings ascribed to them in the Loan Agreement.

B. Secured Party is willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Secured Party a security interest in substantially all of Grantor's personal property whether presently existing or hereafter acquired. To that end, Grantor has executed in favor of Secured Party the Loan Agreement granting a security interest in all Collateral, and is executing this Agreement with respect to certain items of Intellectual Property, in particular.

NOW, THEREFORE, THE PARTIES HERETO AGREE AS FOLLOWS:

1. Grant of Security Interest. As collateral security for the prompt and complete payment and performance of all of Grantor's present or future Obligations, Grantor hereby grants a security interest to Secured Party, as security, in and to Grantor's entire right, title and interest in, to and under the following Intellectual Property, now owned or hereafter acquired by Grantor or in which Grantor now holds or hereafter acquires any interest (all of which shall collectively be called the "Collateral" for purposes of this Agreement):

(a) Any and all copyrights, whether registered or unregistered, held pursuant to the laws of the United States, any State thereof or of any other country; all registrations, applications and recordings in the United States Copyright Office or in any similar office or agency of the United States, and State thereof or any other country; all continuations, renewals, or extensions thereof; and any registrations to be issued under any pending applications, including without limitation those set forth on Exhibit A attached hereto (collectively, the "Copyrights");

(b) All letters patent of, or rights corresponding thereto in, the United States or any other country, all registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto in, the United States or any other country, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country; all reissues, continuations, continuations-in-part or extensions thereof; all petty patents, divisionals, and patents of addition; and all patents to be issued under any such applications, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");

(c) All trademarks, trade names, corporate names, business names, trade styles, service marks, logos, other source or business identifiers, prints and labels on which any of the foregoing have appeared or appear, designs and general intangibles of like nature, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and any applications in connection therewith, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof, and reissues,

extensions or renewals thereof, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the "Trademarks");

(d) Any and all claims for damages by way of past, present and future infringement of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(e) All licenses or other rights to use any of the Copyrights, Patents or Trademarks, and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(f) All amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents; and

(g) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding the foregoing the term "Collateral" shall not include: (a) "intent-to-use" trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise, but only to the extent the granting of a security interest in such "intent to use" trademarks would be contrary to applicable law or (b) any contract, instrument or chattel paper in which Grantor has any right, title or interest if and to the extent such contract, instrument or chattel paper includes a provision containing a restriction on assignment such that the creation of a security interest in the right, title or interest of Grantor therein would be prohibited and would, in and of itself, cause or result in a default thereunder enabling another person party to such contract, instrument or chattel paper to enforce any remedy with respect thereto; provided, however, that the foregoing exclusion shall not apply if (i) such prohibition has been waived or such other person has otherwise consented to the creation hereunder of a security interest in such contract, instrument or chattel paper, or (ii) such prohibition would be rendered ineffective pursuant to Sections 9-407(a) or 9-408(a) of the UCC, as applicable and as then in effect in any relevant jurisdiction, or any other applicable law (including the Bankruptcy Code or principles of equity); provided further that immediately upon the ineffectiveness, lapse or termination of any such provision, the term "Collateral" shall include, and Grantor shall be deemed to have granted a security interest in, all its rights, title and interests in and to such contract, instrument or chattel paper as if such provision had never been in effect; and provided further that the foregoing exclusion shall in no way be construed so as to limit, impair or otherwise affect Secured Party's unconditional continuing security interest in and to all rights, title and interests of Grantor in or to any payment obligations or other rights to receive monies due or to become due under any such contract, instrument or chattel paper and in any such monies and other proceeds of such contract, instrument or chattel paper.

2. Covenants and Warranties. Grantor represents, warrants, covenants and agrees as follows:

(a) Grantor has rights (as defined in the UCC) in the Collateral, except for Permitted Liens;

(b) During the term of this Agreement, Grantor will not transfer or otherwise encumber any interest in the Collateral, except for Permitted Liens and except for transfers otherwise permitted under the Loan Agreement;

(c) To its knowledge, each of the Patents is valid and enforceable, and no part of the Collateral has been judged invalid or unenforceable, in whole or in part, and no claim has been made that any part of the Collateral violates the rights of any third party;

(d) Grantor shall deliver to Secured Party within thirty (30) days of the last day of each fiscal quarter, a report signed by Grantor, in form reasonably acceptable to Secured Party, listing (i) any

applications or registrations that Grantor has made or filed in respect of any patents, copyrights or trademarks, (ii) the status of any outstanding applications or registrations and (iii) any material change in the composition of the Collateral;

(e) Grantor shall use reasonable commercial efforts to (i) protect, defend and maintain the validity and enforceability of the Trademarks, Patents and Copyrights, (ii) detect infringements of the Trademarks, Patents and Copyrights and promptly advise Secured Party in writing of material infringements detected, and (iii) not allow any material Trademarks, Patents or Copyrights to be abandoned, forfeited or dedicated to the public unless Grantor deems it to be in the best interest of Grantor's business;

(f) Grantor shall apply for registration (to the extent not already registered) with the United States Patent and Trademark Office or the United States Copyright Office, as applicable: (i) those intellectual property rights listed on Exhibits A, B and C hereto within thirty (30) days of the date of this Agreement; and (ii) those additional intellectual property rights developed or acquired by Grantor from time to time in connection with any product or service, prior to the sale or licensing of such product or the rendering of such service to any third party (including without limitation revisions or additions to the intellectual property rights listed on such Exhibits A, B and C), except, in each case, with respect to such rights that Grantor determines in its sole but reasonable commercial judgment need not be registered to protect its own business interests. Grantor shall, from time to time, execute and file such other instruments, and take such further actions as Secured Party may reasonably request from time to time to perfect or continue the perfection of Secured Party's interest in the Collateral; and

(g) Grantor shall not enter into any agreement that would materially impair or conflict with Grantor's obligations hereunder without Secured Party's prior written consent, which consent shall not be unreasonably withheld. Grantor shall not permit the inclusion in any material contract to which it becomes a party of any provisions that could or might in any way prevent the creation of a security interest in Grantor's rights and interests in any property included within the definition of the Collateral acquired under such contracts, except for provisions in such material contracts as are referenced in the last paragraph of Section 1 of this Agreement.

3. Further Assurances; Attorney in Fact.

(a) On a continuing basis, Grantor will make, execute, acknowledge and deliver, and file and record in the proper filing and recording places in the United States, all such instruments, including appropriate financing and continuation statements and collateral agreements and filings with the United States Patent and Trademark Office and the Register of Copyrights, and take all such action as may reasonably be deemed necessary or advisable, or as reasonably requested by Secured Party, to perfect Secured Party's security interest in all Copyrights, Patents and Trademarks and otherwise to carry out the intent and purposes of this Agreement, or for assuring and confirming to Secured Party the grant or perfection of a security interest in all Collateral.

(b) Grantor hereby irrevocably appoints Secured Party as Grantor's attorney-in-fact, with full authority in the place and stead of Grantor and in the name of Grantor, from time to time in Secured Party's discretion, to take any action and to execute any instrument which Secured Party may deem necessary or advisable to accomplish the purposes of this Agreement, including (i) to modify, in its sole discretion, this Agreement without first obtaining Grantor's approval of or signature to such modification by amending Exhibits A, B and C, hereof, as appropriate, to include reference to any right, title or interest in any Copyrights, Patents or Trademarks acquired by Grantor after the execution hereof or to delete any reference to any right, title or interest in any Copyrights, Patents or Trademarks in which Grantor no longer has or claims any right, title or interest, (ii) to file, in its sole discretion, one or more financing or continuation statements and amendments thereto, relative to any of the Collateral without the signature of Grantor where permitted by law, and (iii) after the occurrence and during the continuance of an Event of Default, to transfer the Collateral into the name of Secured Party or a third party to the extent permitted under the California Uniform Commercial Code.

4. Events of Default. The occurrence of any of the following shall constitute an Event of Default under this Agreement:

(a) An Event of Default under the Loan Agreement; or

(b) Grantor breaches in any material respect any warranty or agreement made by Grantor in this Agreement and, as to any breach that is capable of cure, Grantor fails to cure such breach within thirty (30) days of the sooner to occur of Grantor's receipt of notice of such breach from Secured Party or the date on which such breach first becomes known to Grantor.

5. Amendments. This Agreement may be amended only by a written instrument signed by both parties hereto, except for amendments permitted under Section 3 hereof to be made by Secured Party alone.

6. Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same agreement. This Agreement may be executed by electronic signatures. Borrower and Lender expressly agree to conduct the transactions contemplated by this Agreement by electronic means (including, without limitation, with respect to the execution, delivery, storage and transfer of this Agreement by electronic means and to the enforceability of electronic Loan Documents). Delivery of an executed signature page to this Agreement by facsimile or other electronic mail transmission shall be effective as delivery of a manually executed counterpart hereof and thereof, as applicable.

7. Several Nature of Secured Party's Obligations and Rights; Pari Passu Security Interests. This Agreement is and shall be interpreted for all purposes as separate and distinct agreements between Grantor and VLL8, on the one hand, and Grantor and VLL9, on the other hand, and nothing in this Agreement shall be deemed a joint venture, partnership or other association between VLL8 and VLL9. Each reference in this Agreement to "Secured Party" shall mean and refer to each of VLL8 and VLL9, singly and independent of one another. Without limiting the generality of the foregoing, the covenants and other obligations of "Secured Party" under this Agreement are several and not joint obligations of VLL8 and VLL9, and all rights and remedies of "Secured Party" under this Agreement may be exercised by VLL8 and/or VLL9 independently of one another. The security interests granted by Grantor to each of VLL8 and VLL9 hereunder and under the Loan Agreement shall be deemed to have been granted and perfected at the same time and shall be of equal priority.


[Signature Pages Follow]

[Signature page to Intellectual Property Security Agreement]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

GRANTOR:

NEUROPEPTIDE MOLECULAR, INC.

By: 
Name: Jeffrey S. Williams
Title: CEO

Address for Notices:

1250 Eisenhower Pl., Ann Arbor, MI 48108
Attn: Jeffrey S. Williams, CEO
Fax #:
Phone #: (734) 527-0137

SECURED PARTY:

VENTURE LENDING & LEASING VIII, INC.

By: _____
Name: _____
Title: _____

Address for Notices:

104 La Mesa Dr., Suite 102
Portola Valley, CA 94028
Attn: Chief Financial Officer
Fax # 650-234-4343
Phone # 650-234-4300

SECURED PARTY:

VENTURE LENDING & LEASING IX, INC.

By: _____
Name: _____
Title: _____

Address for Notices:

104 La Mesa Dr., Suite 102
Portola Valley, CA 94028
Attn: Chief Financial Officer
Fax # 650-234-4343
Phone # 650-234-4300

[Signature page to Intellectual Property Security Agreement]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

GRANTOR:

NEUMODX MOLECULAR, INC.

By: _____
Name: Jeffrey S. Williams
Title: CEO

Address for Notices:

1250 Eisenhower Pl., Ann Arbor, MI 48108
Attn: Jeffrey S. Williams, CEO
Fax #:
Phone #: (734) 527-0137

SECURED PARTY:

VENTURE LENDING & LEASING VIII, INC.

By: _____
Name: David Wanek
Title: Vice President

Address for Notices:

104 La Mesa Dr., Suite 102
Portola Valley, CA 94028
Attn: Chief Financial Officer
Fax # 650-234-4343
Phone # 650-234-4300

SECURED PARTY:

VENTURE LENDING & LEASING IX, INC.

By: _____
Name: David Wanek
Title: Vice President

Address for Notices:

104 La Mesa Dr., Suite 102
Portola Valley, CA 94028
Attn: Chief Financial Officer
Fax # 650-234-4343
Phone # 650-234-4300

EXHIBIT A

Copyrights

None.

EXHIBIT B

Patents

Docket Number	Type	Filing Date	Application Number	Publication Number	Patent Number	Issue Date
Poi (cartridge)	PRV	13-Feb-2012	61/598,240	n/a	n/a	n/a
	PRV2	03-Jul-2012	61/667,606	n/a	n/a	n/a
	US1	13-Feb-2013	13/765,996	2013-0210125	9,738,887	22-Aug-2017
	US2	13-Feb-2013	13/766,000	2013-0210126	9,433,940	6-Sep-2016
	US3	13-Feb-2013	13/766,999	2013-0209326	9,101,930	11-Aug-2015
	US4	30-Jun-2015	14/755,821	2015-0208119	9,403,165	2-Aug-2016
	US5	14-Jun-2016	15/182,187	2016-0288123	9,452,430	27-Sep-2016
	US6	16-Jan-2017	15/407,160	2017-0120243	TBD	TBD
	US7	01-Dec-2017	15/828,721	2018-0085749	TBD	TBD

49013/0427
JTN/50256.2

Docket Number	Type	Filing Date	Application Number	Publication Number	Patent Number	Issue Date
P02 (overall system and method)	PCT	13-Feb-2013	PCT/US13/25859	WO2013-122995	n/a	n/a
	AU	13-Feb-2013	2013221701	n/a	2013221701	18-May-2017
	CN	13-Feb-2013	2013000091697	104254595	TBD	TBD
	EP	13-Feb-2013	13748851.6	2814942	TBD	TBD
	JP	13-Feb-2013	2014-556810	2015-513346	6061313	unknown
	US1	13-Feb-2013	13/766,359	2013-0210127	9,050,594	9-Jan-2015
	US2	13-Feb-2013	13/766,377	2013-0210015	9,339,812	17-May-2016
	US3	05-May-2015	14/704,215	2015-0232832	9,441,219	13-Sep-2016
	US4	21-Apr-2016	15/134,765	2016-0230215	TBD	TBD
	US5	29-Aug-2016	15/249,771	2016-0362677	TBD	TBD

49013/0427
JTK/530256.2

Docket Number	Type	Filing Date	Application Number	Publication Number	Patent Number	Issue Date
	PCT	13-Feb-2013	PCT/US13/25918	WO2013-123035	n/a	n/a
	CH	13-Feb-2013	20138000092863	104271765	ZL2013800092863	26-Apr-2017
	PRV	25-Oct-2012	61/718,634	n/a	n/a	n/a
	US	30-Jan-2014	14/168,760	2014-0147892	9,382,532	5-Jul-2016
	US2	06-Jun-2016	15/173,880	2016-0281080	9,540,636	10-Jan-2017
Po3 (isolation)	US3	29-Nov-2016	15/363,323	2017-0073668	TBD	TBD
	PCT	22-Oct-2013	PCT/US13/56162	WO2014-066376	n/a	n/a
	EP	22-Oct-2013	13849949.6	2912174	TBD	TBD
	PRV1	14-Mar-2013	61/783,265	n/a	n/a	n/a
Po4 (drift)	PRV2	18-Sep-2013	61/879,513	n/a	n/a	n/a

49013/0427
JTK/530256.2

Docket Number	Type	Filing Date	Application Number	Publication Number	Patent Number	Issue Date
	US	16-Sep-2014	14/487,808	2015-0079666	9,499,896	22-Nov-2016
	US2	19-Oct-2016	15/297,736	2017-0036209	TBD	TBD
	PVP	18-Sep-2013	60/579,607	n/a	n/a	n/a
Po5 (wiring)	US	16-Sep-2014	14/487,837	2015-0079667	9,539,576	10-Jan-2017
	US2	29-Nov-2016	15/363,107	2017-0072400	TBD	TBD
Po6 (reverse 2D cam)	US	28-Mar-2014	14/229,996	2014-0227146	9,637,775	2-May-2017
	US2	22-Mar-2017	15/465,796	2017-0191115	TBD	TBD
	US3					
	PCT	30-Mar-2015	PCT/US15/03280	WO2015/149057	n/a	n/a

Docket Number	Type	Filing Date	Application Number	Publication Number	Patent Number	Issue Date
	CN	28-Nov-2016	2015800283319	106414771	TBD	TBD
	EP	12-Oct-2016	15768435.8	3122903	TBD	TBD
	PRV	09-Nov-2016	62/419,578	n/a	n/a	n/a
P07 (cartridge updates)	US	09-Nov-2017	15/808,183	2018-0066248	TBD	TBD
	PRV	10-Oct-2014	62/665,300	n/a	n/a	n/a
P08 (improved system and method) (CIP of P02)	US	04-Feb-2014	14/613,616	2015-0151300	9,604,233	28-Mar-2017
	US2	24-Jan-2017	15/413,735	2017-0128946	10,010,886	3-Jul-2018
	US3	04-Jun-2018	15/996,949	TBD	TBD	TBD

EXHIBIT C

Trademarks

Description
NeuMoDx

Registration/Application Number
Serial No. 87/175,050

Registration/Application Date
September 19, 2016

49013/0427
JTK/530256.2